Disclosures. Bisphosphonate Treatment for Osteoporosis: Do the Benefits Outweigh the Risks? Risks vs Benefits. Bisphosphonates: Benefits and Risks
|
|
- Lizbeth Bryan
- 6 years ago
- Views:
Transcription
1 Bisphosphonate Treatment for steoporosis: Do the Benefits utweigh the Risks? 37 th Annual Advances in Internal Medicine May 18 and June 22, 29 hsponsored resentations Disclosures Eli Lilly & Company, GlaxoSmithKline, Merck & Company, ovartis, rocter & Gamble harmaceuticals, Roche, sanofi-aventis, Wyeth hconsultation Steven T Harris MD FAC Clinical rofessor of Medicine University of California, San Francisco Amgen, Eli Lilly & Company, GlaxoSmithKline, Merck & Company, ovartis, rocter & Gamble, Roche, sanofi-aventis, Wyeth Bisphosphonates: Benefits and Risks Risks vs Benefits hefficacy Short-term efficacy usually established on the basis of fracture risk reduction over 3 years Long-term efficacy (Is treatment forever? ) hsafety Short-term concerns Long-term concerns that have been raised hcost both economic and quality of life hsteonecrosis of the jaw (J) hatrial fibrillation habnormal bone quality/atypical fractures hesophageal cancer
2 FDA-Approved Therapeutic ptions in the USA revention Stops bone loss Estrogen Treatment Reduces vertebral fractures Calcitonin (Miacalcin, Fortical ) Alendronate (Fosamax ) Risedronate (Actonel ) Ibandronate (Boniva : oral, injection) Zoledronic acid (Reclast : infusion) Raloxifene (Evista ) TH (Forteo ) on-itrogen-containing Bisphosphonates CH 3 H Etidronate Cl Cl Clodronate itrogen-containing Bisphosphonates Alkyl H 2 H 2 CH 3 H amidronate H Alendronate H Ibandronate Heterocyclic H Risedronate H Zoledronic acid Bisphosphonates Alendronate, Risedronate, Ibandronate and Zoledronic Acid A number of different bisphosphonates are now available for the prevention and treatment of osteoporosis in daily oral, intermittent oral and intermittent parenteral formulations: h Alendronate 1 mg daily or 7 mg weekly for treatment, mg daily or 3 mg weekly for prevention h Risedronate mg daily or 3 mg weekly; 7 mg on two consecutive days once each month, 1 mg monthly h Ibandronate 2. mg daily or 1 mg monthly by mouth; 3 mg iv over 1-3 seconds every 3 months h Zoledronic acid mg by infusion over a minimum of 1 minutes every year Bisphosphonates: Indications Alendronate, Risedronate, Ibandronate and Zoledronic Acid h Treatment and prevention of postmenopausal osteoporosis (alendronate, risedronate and ibandronate) h Treatment of postmenopausal osteoporosis (zoledronic acid) h Treatment and prevention of glucocorticoid-induced osteoporosis (risedronate, zoledronic acid) h Treatment of glucocorticoid-induced osteoporosis (alendronate) h Treatment of men with low bone density (alendronate, risedronate, zoledronic acid)
3 Bisphosphonates: 24-month BMD Changes Trials of Different Agents Cannot Be Compared Directly % Change in BMD 7 6 RIS 3 mg weekly1 4 AL 7 mg weekly1 3 IB 1 mg monthly 2 ZL mg iv annually Spine Total Hip Fracture Endpoints hregulatory approval of existing medications has been based on fracture reduction, rather than changes in surrogates such as bone mineral density (BMD) alone hwith the exception of the annual infusion of zoledronic acid, the approval of all current bisphosphonates has been based on pivotal trials conducted with daily therapy hthere are no controlled trials showing that weekly or monthly bisphosphonate therapy reduces fracture risk; the results of daily therapy have been bridged to weekly and monthly therapy 1 Bonnick S, et al. J Clin Endocrinol Metab 26;91: Reginster J-Y, et al. Ann Rheum Dis 26;6: Black DM, et al. Engl J Med 27;36: Fracture Endpoints, con t hthe most common fracture endpoint has been the reduction in vertebral fracture Vertebral fracture has most often been defined by morphometric changes, including both new and worsening fractures Clinical vertebral fracture defined as fracture associated with back pain has usually been identified as a secondary endpoint h on-vertebral fracture has most commonly been identified as a secondary endpoint as well Varying definitions of non-vertebral fracture : all fractures vs fragility fractures vs a particular composite endpoint of fractures Hip fracture has sometimes but not always been identified as a separate endpoint of particular interest Fracture Endpoints, con t hfracture reduction has most often been expressed both clinically and commercially as relative risk reduction, rather than absolute risk reduction hthe rapidity with which fracture protection occurs has been of clinical and commercial interest hthere are no head-to-head randomized trials with fracture as the primary endpoint hthe pivotal fracture trials recruited patients with a certain sameness but there were notable differences in demographics, baseline fracture status and baseline BMDs nevertheless There were obvious differences in observed fracture rates both vertebral and non-vertebral
4 Bisphosphonates: Clinical Trial Results Trials of Different Agents Cannot Be Compared Directly Vertebral Fracture Effects In rospective Trials Direct Comparisons Among Trials Cannot Be Made Effect on fracture risk Agent Spine on-spine Hip Alendronate Risedronate Ibandronate + - Zoledronic acid documented in a randomized, controlled trial; effect not documented effect documented only in a post hoc analysis of a high-risk sub-group (femoral neck T score < -3) and in a meta-analysis of clinical trials (Harris ST, et al. Curr Med Res pin 28;24:237-24) % of atients With ew Vertebral Fractures ver 3- Years % Calcium CT RLX AL RIS IB ZL 3% 47% RF MRE FIT-VFA VERT-A VERT-M BE HRIZ MRE FIT-CFA With revalent Vertebral Fractures ± Vert Fx Chesnut CH, et al. Am J Med. 2;19:267 Ettinger B, et al. JAMA. 1999;282:637 Black DM, et al. Lancet. 1996;348:13 Cummings SR, et al. JAMA. 1998;28:277 Harris ST, et al. JAMA. 1999;282:1344 Reginster J, et al. steoporos Int. 2;11:83 Chesnut CH, et al. J Bone Miner Res. 24;19:1241 Black DM, et al. Engl J Med 27:36:189 41% 49% % Relative Fracture Risk Reduction 2% 7% % % Without Vert Fx % of atients With ew onvertebral Fractures ver 3- Years onvertebral Fracture Effects In rospective Trials Direct Comparisons Among Trials Cannot Be Made * % p n.s. Calcium CT RLX AL RIS IB ZL 1% p n.s. 2% p.6 12% p n.s. % Relative Fracture Risk Reduction 39% p <. 33% p.6 p n.s. 2% p <.1 RF MRE FIT-VFA FIT-CFA VERT-A VERT-M BE HRIZ Fracture Endpoints h If existing randomized clinical trials cannot address all issues of clinical relevance, then additional insights can be gathered from: ost hoc analyses of existing trial data Meta analyses of existing trial data bservational data Chesnut CH, et al. Am J Med. 2;19:267 Ettinger B, et al. JAMA. 1999;282:637 Black DM, et al. Lancet. 1996;348:13 Cummings SR, et al. JAMA. 1998;28:277 Harris ST, et al. JAMA. 1999;282:1344 Reginster J, et al. steoporos Int. 2;11:83 Chesnut CH, et al. J Bone Miner Res. 24;19:1241 Black DM, et al. Engl J Med 27:36:189 * atient demographics and the definition of nonvertebral fracture varied among studies
5 Fracture incidence (%) Monthly Ibandronate vs Weekly Bisphosphonates at 12 Months 1.6 RR.88 p Fx738 Fx9 Monthly oral ibandronate (n7,34) Weekly oral Bs (n6,837) RR1.6 p.84 Fx1 RR.36 p< Fx16 RR.82 p.2 RR adjusted RR (hazard ratio) using Cox regression controlling for potential confounders Fx13 Fx88 Fx13 on-vertebral Hip Vertebral Any Fractures Fx Bisphosphonate Trials: Summary hwe have available for use four -containing bisphosphonates, all of which share a common mechanism of action h There are pharmacokinetic differences among the bisphosphonates, but the clinical implications of those differences are not firmly established hthe induced changes in BMD with the four bisphosphonates may be subtly different, but all reduce fracture to a greater extent than one would predict from the change in BMD alone; i.e., they all improve bone quality Harris ST, et al. Bone 29;44:78-76 Bisphosphonate Trials: Summary, con t steoporosis: Extended Therapy? hit is possible to compare the pivotal trials of different treatment agents vis-à-vis fracture endpoints but it is much more difficult to draw firm clinical conclusions from those comparisons hthe pivotal trials studied similar populations of postmenopausal women, but there were nevertheless important differences in demographics, inclusion criteria and fracture endpoints h Absence of evidence is not evidence of absence h The safety record of contemporary treatment agents is excellent, but there is a remaining concern about potential long-term skeletal toxicity, particularly with long-lived agents such as the bisphosphonates h It s not clear if treatment should be continued indefinitely, interrupted with a drug holiday, or terminated
6 Bisphosphonate Therapy h Bone biopsies after years of risedronate therapy 1 and 1 years of alendronate therapy 2 have shown no histologic abnormalities h Fracture rates remain low after 7 years of risedronate therapy 3 and 1 years of alendronate therapy 4, 1. Ste-Marie LG, et al. Calcif Tissue Int. 24;7: Recker RR, et al. J Bone Miner Res. 24;19(suppl 1):S4 3. Mellstrom DD, et al. Calcif Tissue Int. 24;7: Bone HG, et al. Engl J Med. 24;3:1189. Black DM, et al. Engl J Med 27;36:189 Incidence per year (%) Vertebral Fractures ver 7 Years of Risedronate Therapy VERT-M: Radiographic Vertebral Fracture* Years -3 Years 4- Subjects switched to risedronate mg at end of year lacebo Ris mg lacebo Ris mg Ris mg Ris mg Years 6-7 *Annualized fracture incidence represents the percentage of patients experiencing any new vertebral fracture divided by the number of years in the observed interval. FIT Long-Term Extension (FLEX) h Women previously on alendronate for 3-6 years were randomly assigned to years of alendronate ( or 1 mg daily) or placebo h Alendronate vs placebo Clinical spine fracture: RR.4 (.23,.84) Morphometric spine fracture: RR.87 (.61, 1.2) onspine fracture: RR1. (.76, 1.32) Black DM, et al. JAMA 26;296: Mean ercent Change From FIT Baseline, % FLEX: % Change in Spine BMD FIT 3 to 4. years F F 1 F 2 F 3 F 4 FL FL 1 FL 2 FL 3 FL 4 FL AL/lacebo (n 437) AL/AL (pooled -mg and 1-mg groups: n662) Black DM, et al. JAMA 26;296: Time Between FIT and FLEX 1 to 2 years Year FLEX years 3.7% <.1
7 Mean ercent Change From FIT Baseline, % FLEX: % Change in Femoral eck BMD FIT 3 to 4. years F F 1 F 2 F 3 F 4 FL FL 1 FL 2 FL 3 FL 4 FL AL/lacebo (n 437) AL/AL (pooled -mg and 1-mg groups: n662) Black DM, et al. JAMA 26;296: Time Between FIT and FLEX 1 to 2 years Year FLEX years 1.9% <.1 Fracture Incidence, % FLEX: Incidence of Fractures Relative Risk Reduction % ARR 2.9%.13 RR.4 CI (.2,.8) AL/LB (n 437) AL/AL (n 662) RR.9 CI (.6, 1.2) RR 1. CI (.8, 1.4).3% 2.4% 11.3% 9.8% 19.% 18.9% Clinical Vertebral Vertebral Morphometric on-vertebral Black DM, et al. JAMA 26;296: FLEX Summary and Conclusions h ver 1 years (FIT and FLEX), continuous alendronate treatment: revented bone loss at the total hip and increased BMD at the femoral neck and lumbar spine Maintained biochemical markers of bone turnover at levels similar to FLEX baseline Reduced the relative risk of clinical vertebral fracture by % (ARR 2.9%) Resulted in normal bone histology h Discontinuation of alendronate treatment in FLEX: Resulted in a loss of total hip and femoral neck BMD Led to a rise in biochemical markers of bone turnover Resulted in more clinical vertebral fractures but had no effect on morphometric vertebral fractures or non-vertebral fractures in the entire study group Black DM, et al. JAMA 26;296: FLEX: VF Risk with Extended Alendronate Therapy Stratified by Baseline Femoral eck BMD 199 patients enrolled in FLEX 723 with no vertebral fracture at FLEX baseline Baseline F BMD Risk Difference Relative Risk T-score > % 1.41 (.7, 2.66) T-score %. (.26,.96) Schwartz AV, et al. Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: The FLEX Trial. ASMBR 29 th Annual Meeting, resentation 17
8 Bisphosphonates: Side Effects h Class warning regarding UGI symptoms (no increase in UGI complaints in randomized controlled trials) h Class warning regarding infrequent bone, joint and/or muscle pain h Class warning regarding jaw osteonecrosis hinfluenza-like symptoms may occur after first monthly oral dose or IV injection steonecrosis f The Jaw (J) h An area of exposed alveolar or palatal bone that typically shows poor healing over several months. rior to bisphosphonate use, J was described in HIV and in osteopetrosis. ow associated uncommonly with high dose, chronic IV bisphosphonate treatment of myeloma and cancer metastatic to bone (9% of reported cases) 1 ain in 2/3 of cases: infection may or may not be present. Known risk factors: invasive dental procedures (tooth extraction or implants), oral trauma, periodontitis, poor oral hygiene, radiotherapy to the jaw, chemotherapy, corticosteroids, infection athogenesis is not known 2 1 Woo SB, et al. Ann Intern Med. 26;144:73 2 Khosla S, et al. J Bone Miner Res. 27;22: steonecrosis f The Jaw In atients Taking Bisphosphonates For steoporosis hj reported rarely in patients taking oral bisphosphonates for osteoporosis or aget s disease of bone 1 ho reports of J in controlled clinical trials (most of 2-3 years duration) involving 6, patient years of exposure to oral bisphosphonate therapy for osteoporosis 2 Includes over 3,88 patients in long-term trials of 3-1 years of continuous bisphosphonate use htwo cases of J in zoledronic acid osteoporosis trial 1 in the placebo group and 1 in the zoledronic acid group 3 1 Woo SB, et al. Ann Intern Med. 26;144:73 2 Khosla S, et al. J Bone Miner Res. 27;22: Black DM, et al. Engl J Med. 27;36:189 Bisphosphonate-Related J: Incidence The Background Incidence in the General opulation is ot Known Underlying Malignancy steoporosis aget s Disease IV 1% to 1% Rate not published Rate not published Khosla S, et al. J Bone Miner Res 27;22; /1, to <1/1, patient-treatment-years
9 J recautions And Management * hatients beginning a bisphosphonate for osteoporosis Ensure that patient is in a regular program of oral hygiene. If not, program should begin. Ideally, invasive procedures should be completed prior to bisphosphonate therapy, if possible hatients on bisphosphonates for osteoporosis Routine dental care (cleaning, hygiene, filings, etc) as recommended for the general population without the need to interrupt bisphosphonate therapy Dental surgery (extractions, implants, etc) should be limited to that required for good dental health and only when more conservative approaches are either not indicated or not effective h o data available to suggest whether temporary discontinuation of bisphosphonate treatment during dental treatment reduces J risk hatients with complaints referable to the oral mucosa or to underlying bone should be referred to a dentist or oral surgeon Atrial Fibrillation: FDA Review Updated 28 h n ctober 1, 27, FDA announced that it was reviewing safety data that raised concerns about a potential increased risk for atrial fibrillation in patients treated with a bisphosphonate drug. An article and an accompanying letter to the editor in the May 3, 27, issue of The ew England Journal of Medicine described increased rates of serious atrial fibrillation in two different studies of women ages 6 to 89 years old with osteoporosis treated with the bisphosphonates, Reclast and Fosamax After our review, based on the data available at this time, healthcare professionals should not alter their prescribing patterns for bisphosphonates and patients should not stop taking their bisphosphonate medication. h n ctober 1, 27, FDA began requesting placebo-controlled clinical trial information from the sponsors of alendronate, ibandronate, risedronate, and zoledronic acid in order to explore the potential risk for atrial fibrillation in male and female patients treated with these bisphosphonate drugs. The data submitted by the four sponsors included data on 19,687 bisphosphonate-treated patients and 18,38 placebo-treated patients who werefollowed for 6 months to 3 years. h The occurrence of atrial fibrillation was rare within each study, with most studies containing 2 or fewer events. The absolute difference in event rates between each of the bisphosphonate and placebo arms varied from -3 per 1,. h ne large study of zoledronic acid showed a statistically significant increase in the rate of serious atrial fibrillation events. However, across all studies, no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation was observed. Increasing dose or duration of bisphosphonate therapy was also not associated with an increasedrate of atrial fibrillation. * Adapted from Council on Scientific Affairs of American Dental Assoc Atypical Fractures There has been a theoretical concern that oversuppression of bone remodeling could impair the repair of microdamage and increase the risk of atypical fractures There are several small series of cases: - often fractures of femoral diaphysis - transverse rather than spiral fracture - often on other drugs, especially steroids or estrogen - some with stress reaction or stress fracture and prodromal pain syndrome There is no consensus about the frequency with which these atypical fractures might occur 1. Goh S-K, et al. J Bone Joint Surg Br. 27;89: Imai K, et al. J Bone Miner Metab. 27;2: eviaser AS, et al. J rthop Trauma. 28;22: dvina C, et al. J Clin Endo Metab. 2;9: Bisphosphonate Therapy h Long-term treatment has not clearly been associated with safety issues or loss of efficacy h In high-risk patients, continued treatment seems reasonable; there is no mandate to stop treatment h Cessation of treatment after 2- years is associated with some persisting effect on biochemical markers, as well as BMD; this has been best characterized for alendronate h The limited available data suggest a persisting effect on fracture risk; this has again been best characterized for alendronate
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationDrugs Approved for Prevention and Treatment of Postmenopausal Osteoporosis
Other Treatments of Osteoporosis- Who Should Get Bisphosphonates David Slovik, M.D. Endocrine Unit Newton-Wellesley Hospital Massachusetts General Hospital Harvard Medical School Massachusetts Medical
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationEffective Health Care
Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationEndocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni. Hot topics in osteoporosis. How long to treat
Endocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni Hot topics in osteoporosis How long to treat Dott. Bruno Madeo bruno.madeo@unimore.it www.endocrinologia.unimore.it/on-line/home.html
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationHow long to treat? Disclosure. What is the real problem? Conclusions
Disclosure How long to treat? 11 th Annual Update on Osteoporosis and Skeletal Health Institutional Grant / Research Support Amgen, Eli Lilly, Merck Consulting / Speaking Amgen, Eli Lilly, Merck, Radius
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationPROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE
CASES AUTH/1803/2/06 and AUTH/1804/2/06 PROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE Bonviva Once Monthly slide kits Procter & Gamble and Sanofi-Aventis complained jointly about two
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationDisclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationRheumatology. keeping Joints in Motion. Treating and Preventing Fractures
Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationEpidemiology and Consequences of Fractures
Epidemiology and Consequences of Fractures Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Financial Disclosures Advisory Board: Amgen Research Support: Hologic 24July12 1 Outline
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis Treatment Update
//7 steoporosis Treatment Update What is steoporosis? steoporosis is a skeletal disorder characterised by compromised bone strength predisposing a person to an increased risk of fracture. rofessor T.Masud
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationTreatment of Osteoporosis: IHFD 6 th March 2015
Treatment of Osteoporosis: IHFD 6 th March 2015 Dr. John J. Carey, MB, MS, FACR, FRCPI, CCD. Consultant Physician Galway University Hospitals Associate Professor in Medicine, NUIG, Galway Vice-President
More informationReducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.
Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationBisphosphonates. Making intelligent drug choices
Making intelligent drug choices Bisphosphonates are a first choice for treating osteoporosis, according to Kedrin E. Van Steenwyk, DO, an obstetrician/gynecologist at Sycamore Women s Center, Miamisburg,
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationBisphosphonate Step Therapy Criteria
ϯ ϯ ϯ A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association Bisphosphonate Step Therapy Criteria Program may
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More information1/28/2017. Orthopedic Implications Of Osteoporosis Introduction. Orthopedic Implications Of Osteoporosis Introduction
The Orthopedic Implications Of Prolonged In Osteoporosis Donald A. Wiss MD Director Of Orthopedic Trauma Cedars Sinai Medical Center Orthopedic Implications Of Osteoporosis Introduction Osteoporosis Most
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationBone Health for Women: Current Research, Initiatives and Recommendations
Page 1 BONE HEALTH FOR WOMEN: CURRENT RESEARCH, INITIATIVES AND RECOMMENDATIONS Dr. Melissa Kagarise This program has been brought to you by PharmCon PharmCon is accredited by the Accreditation Council
More informationPostmenopausal osteoporosis is a systemic
OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More information